Immutep LtdASX: IMM

Late-Breaking Abstract on IMP761 to be presented at ACR 2026

Oct 18, 2026 at 5:10 PM EDT · Issued by Immutep Ltd via ASX

Filed with ASX · Oct 18, 2026 at 5:10 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/late-breaking-abstract-on-imp761-to-be-presented-at-acr-2026

Release

Immutep Limited, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889 Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026 • Late-breaking poster will present data from the first-in-human Phase I...

Immutep Ltd on 6ix

Story so far

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Jul 24, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingApr 22, 2026

Earlier from Immutep

2026 Annual General Meeting and Key DatesOct 14
Immutep & Monash Secure Further ARC Funding for LAG-3Oct 13
Immutep Regains Compliance with NasdaqOct 12
Audit and Risk Committee UpdateOct 9
Final Director's Interest Notice - P MeyersOct 4

Later from Immutep

Quality of Life Data from EFTISARC-NEO presented at ESMOOct 23
Annual Report filed on Form 20-FOct 25
Annual Report to shareholdersOct 26
Appendix 4G and Corporate Governance StatementOct 26
Notice of Annual General Meeting/Proxy FormOct 26

All Immutep news releases

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep